Einstein became the rare physicist who understood that fame is an asset class. His name licensing deal with the Hebrew University—reportedly worth $2M+ annually—turned his iconic status into a perpetual revenue stream. This is pure business acumen: he didn't invent the licensing model, but his estate executed it flawlessly. Curie, by contrast, treated her discoveries like public property. She refused to patent radium extraction, leaving billions on the table. In today's terms, she handed a pharmaceutical company's worth of IP to the world for free. One chose the mogul path; the other chose the martyr path.

The patent portfolio difference is staggering. Einstein's refrigeration patent—never commercialized during his lifetime—still sits as a valuable asset generating licensing revenue through his estate. Curie's refusal to patent meant zero passive income from her breakthroughs. Radium alone could have funded a personal empire; instead, her legacy is institutional. She died with lab debt while Einstein's executors turned his name into dividends. This is the difference between seeing yourself as a brand versus seeing yourself as a scientist.

There's also a structural timing factor. Einstein died in 1955 when intellectual property law was evolving and celebrity licensing was becoming sophisticated. His estate had modern tools to monetize. Curie died in 1934, but even if she'd survived longer, her ethos wouldn't allow it—she contaminated herself with radium partly because she viewed safety precautions as less important than research progress. She was playing a different game entirely. The $7M gap isn't really about who was smarter; it's about who built financial infrastructure around their genius, and who handed their genius away.